Endometriosis Patients Undergoing Quinagolide Treatment

Instituto Valenciano de Infertilidad, IVI VALENCIA

Status and phase: Completed; Phase 4

Conditions: Endometriosis; Hyperprolactinemia

Treatments: Procedure: ENDOMETRIAL BIOPSY

Study type: Interventional

Funder types: Other

Identifiers

NCT00625950

VLC-AP-10208-208-1

Details and patient eligibility

About

Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.

Enrollment: 5 estimated patients

Sex: Female

Ages: 18 to 37 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Hyperprolactinemia
• Unexplained infertility
• Endometriosis

Trial design

Primary purpose: Health Services Research

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)